IL6 and Parkinson disease: Compared to FTY720-NOB-PLGA NPs,which reduce acute lung injury by limiting macrophage recruitmentand lowering IL-6 and ROS without affecting T cells, FTY720 nanoparticleshave demonstrated promise in treating Parkinson’s disease andenhancing postorgan transplantation survival through different immunomodulatorymechanisms.